Source: https://www.prarulebook.co.uk/pra-rules/credit-valuation-adjustment-risk/01-01-2027?p=1 · captured 2026-09-28 · checked 2026-09-28 · 7d85aec8

801
802where:
803
804N = the re-margining period specified in the margin agreement.
805
80601/01/2027
807
8085.10
809
810A firm must:
811
812(1) obtain the simulated paths of discounted future exposure from the exposure models used by the firm for calculating CVA under the firm’s applicable accounting framework, adjusted as necessary to meet the requirements of this Chapter; and
813
814(2) use the same model calibration process (with the exception of the margin period of risk), market and transaction data as it uses for calculating CVA under the firm’s applicable accounting framework.
815
81601/01/2027
817
8185.11
819
820A firm must ensure the generation of market risk factor paths underlying its exposure models comply with the following requirements:
821
822(1) drifts of risk factors are consistent with a risk-neutral probability measure and not historical calibration of drifts;
823
824(2) the volatilities and correlations of risk factors are calibrated to:
825(a) market data, if sufficient data exist in a given market; or
826
827(b) historical market data, if sufficient data is not available; and
828
829(3) the distribution of modelled risk factors account for the possible non-normality of the distribution of exposures.
830
83101/01/2027
832
8335.12
834
835A firm must ensure that its calculation of regulatory CVA recognises netting sets in the same manner in which the firm calculates CVA under the firm’s applicable accounting framework.
836
83701/01/2027
838
839Qualitative requirements
840
8415.13
842
843A firm must ensure that:
844
845(1) its exposure models used for calculating regulatory CVA are part of a CVA risk management framework that includes the identification, measurement, management, approval and internal reporting of CVA risk;
846
847(2) its senior management is actively involved in the risk control process and must regard CVA risk control as an essential aspect of the business to which sufficient resources are devoted;
848
849(3) it has a process for ensuring compliance with a documented set of internal policies, controls and procedures concerning the operation of the exposure system it uses for calculating CVA under the firm’s applicable accounting framework;
850
851(4) it maintains an independent control unit that is responsible for the effective initial and ongoing validation of its exposure models, which is:
852(a) independent from the business credit and trading units, including the CVA desk;
853
854(b) adequately staffed; and
855
856(c) reports directly to senior management of the firm;
857
858(5) its documentation of the process for initial and ongoing validation of its exposure models:
859(a) is detailed enough to enable a third party to understand how the models operate, their limitations, and their key assumptions, and to recreate the analysis;
860
861(b) sets out the minimum frequency with which ongoing validation will be conducted as well as other circumstances under which additional validation will be conducted; and
862
863(c) describes how the validation is conducted with respect to data flows and portfolios, what analyses are used and how representative counterparty portfolios are constructed;
864
865(6) the pricing models used to calculate exposure for a given path of risk factors must:
866(a) be tested against appropriate independent benchmarks for a wide range of market states as part of the initial and ongoing model validation process; and
867
868(b) for options, account for the non-linearity of option value with respect to risk factors;
869
870(7) its internal audit function carries out an independent review of the overall CVA risk management process on a regular basis, covering both the activities of the CVA desk and the independent risk control unit;
871
872(8) it defines criteria against which to assess the exposure models and their inputs, and has a written policy describing the process to assess performance of the exposure models and remedy unacceptable performance;
873
874(9) its exposure models capture transaction-specific information in order to aggregate exposures at the level of the netting set;
875
876(10) it assigns transactions to the appropriate netting set within the model;
877
878(11) it reflects transaction terms and specifications in its exposure models in a timely, complete and conservative fashion;
879
880(12) it stores transaction terms and specifications in a secure database that is subject to formal and periodic internal audit;
881
882(13) it subjects the transmission of transaction terms and specifications data to the exposure model to internal audit and formal reconciliation processes are in place between the exposure model and source data systems to verify on an ongoing basis that transaction terms and specifications are reflected in the exposure model appropriately;
883
884(14) it uses in its exposure models current and historical market data that is:
885(a) acquired independently of the lines of business and is compliant with the firm’s applicable accounting framework;
886
887(b) fed into the exposure models in a timely and complete fashion;
888
889(c) maintained in a secure database subject to periodic internal audit; and
890
891(d) subject to a well-developed data integrity process to handle erroneous or anomalous data observations; and
892
893(15) it sets internal policies to identify suitable proxies where its exposure models rely on proxy market data and it can demonstrate empirically on an ongoing basis that the proxy provides a conservative representation of the underlying risk under adverse market conditions.
894
89501/01/2027
896
897Delta and vega risks
898
8995.14
900